---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-027191"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T11:56:04.894226+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Genprex gets US and EU patent allowances for REQORSA combo with PD-L1/PD-1 antibodies; trial underway

## Summary
- USPTO issued notice of allowance for patent covering REQORSA + PD-L1 antibodies (e.g., Tecentriq); EPO issued allowance for REQORSA + PD-1 antibodies; both expire 2037.
- Korea granted patent for REQORSA + PD-L1 antibodies; Genprex pursuing additional patents in Europe, Canada, Brazil, China, Israel for Acclaim-3 trial.
- Patents for REQORSA + PD-1 antibodies already granted in US, Japan, Mexico, Russia, Australia, Chile, China, Korea, and Singapore.
- Acclaim-3 Phase 1/2 trial testing REQORSA + Tecentriq maintenance in ES-SCLC has FDA Fast Track and Orphan Drug Designation.

## SEC filing metadata
- accession: 0001437749-25-027191
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925027191/0001437749-25-027191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925027191/gnpx20250815_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-027191
- JSON: https://secwatch.observer/filing/0001437749-25-027191.json
- Plain text: https://secwatch.observer/filing/0001437749-25-027191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.